BioSpace5d
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...
Sutro Biopharma and Boehringer Ingelheim BioXcellenceâ„¢ collaboration: Established first-in-class cell-free capabilities at commercial scale
Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc.today announced that they successfully applied Sutro’ ...
Synaffix B.V.: Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology
AMSTERDAM, BASEL, Switzerland and INGELHEIM, Germany, Jan. 9, 2025 /PRNewswire/ -- Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing ...
Contract Pharma6d
Boehringer Ingelheim Licenses Synaffix ADC Technology
Boehringer Ingelheim has licensed Synaffix B.V.’s ADC technology, significantly bolstering its ADC portfolio with the goal of ...